FOLD - Amicus Corp Total Debt to Capital

The current price action for the total debt-to-equity ratio of Amicus Therapeutics (FOLD) stands at 1.61. The business relies on developing treatments to correct genetic defects, where growth is contingent upon FDA approvals. Amicus Therapeutics attracts experts through humanitarian goals and generous stock options. Team loyalty is driven by the ability to see tangible therapy results, which ensures high staff stability.

Total debt-to-equity measures the degree of financial leverage by comparing total liabilities to equity to assess bankruptcy risks and the stability of the balance sheet structure. For Amicus Therapeutics (FOLD), which relies on a stable staff of scientists and expansion into commercialization, the history of the debt-to-equity ratio serves as an indicator of the ability to fund R&D without a critical debt load.